Summary

Atopic dermatitis (AD) is a common, chronic skin condition induced by a type 2 helper T cell-mediated response to various environmental antigens. These cells release cytokines that promote occurrence and recurrence of AD. This article reviews safety and efficacy results from the phase 2b Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis [NCT01859988].